Takeda, Nectar Plan to Test New IO Combination in non-Hodgkin Lymphoma Patients
News
Nektar Therapeutics and Takeda Pharmaceutical are working together to evaluate a new therapy combining a lead investigational compound from each company — NKTR-214 and TAK-659N — in people with blood cancers ... Read more